Atlas Venture Life Science Advisors LLC Has $5.61 Million Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 21.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 186,979 shares of the company’s stock after selling 50,000 shares during the period. Dianthus Therapeutics makes up about 0.5% of Atlas Venture Life Science Advisors LLC’s investment portfolio, making the stock its 14th biggest position. Atlas Venture Life Science Advisors LLC owned approximately 0.64% of Dianthus Therapeutics worth $5,609,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of DNTH. Vestal Point Capital LP acquired a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $1,404,000. Octagon Capital Advisors LP lifted its position in shares of Dianthus Therapeutics by 15.4% during the fourth quarter. Octagon Capital Advisors LP now owns 554,000 shares of the company’s stock worth $5,762,000 after purchasing an additional 74,000 shares in the last quarter. Hussman Strategic Advisors Inc. acquired a new position in shares of Dianthus Therapeutics during the first quarter worth approximately $630,000. Citigroup Inc. acquired a new position in shares of Dianthus Therapeutics during the third quarter worth approximately $53,000. Finally, Tower Research Capital LLC TRC bought a new stake in shares of Dianthus Therapeutics during the fourth quarter worth approximately $25,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH traded up $0.33 during trading hours on Thursday, hitting $28.97. The stock had a trading volume of 206,090 shares, compared to its average volume of 192,046. Dianthus Therapeutics, Inc. has a one year low of $6.58 and a one year high of $33.77. The company has a market cap of $850.27 million, a price-to-earnings ratio of -4.97 and a beta of 1.89. The business’s 50 day moving average is $24.72 and its 200-day moving average is $22.68.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.11). The business had revenue of $0.87 million for the quarter, compared to analysts’ expectations of $0.48 million. On average, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on DNTH shares. Jefferies Financial Group boosted their price target on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Raymond James boosted their price target on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Wedbush boosted their price target on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Finally, Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating for the company. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $42.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.